Economic burden of sickle cell disease in Brazil

Abstract

Background Sickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of the population has the sickle cell trait in Brazil, and 60,000 to 100,000 have SCD. However, despite recognizing the significant burden of disease, little is known about SCD costs. Objective To estimate SCD societal costs based on disease burden modelling, under Brazilian societal perspective. Methods A disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical and indirect costs (morbidity and mortality). The sum of life lost and disability years was considered to estimate disability-adjusted life years (DALYs). Data from a public database (DATASUS) and the prevalence obtained from literature or medical experts were used to define complications prevalence and duration. Costs were defined using data from the Brazilian public healthcare system table of procedures and medications (SIGTAP) and the human capital method. Results Annual SCD cost was 413,639,180 USD. Indirect cost accounted for the majority of burden (70.1% of the total; 290,158,365 USD vs 123,480,816 USD). Standard of care and chronic complications were the main source of direct costs among adults, while acute conditions were the main source among children. Vaso-occlusive crisis represented the complication with the highest total cost per year in both populations, 11,400,410 USD among adults and 11,510,960 USD among children. Conclusions SCD management may impose an important economic burden on Brazilian society that may reach more than 400 million USD per year.

Frequency of red blood cell transfusions in preterm neonates in Brazil: A systematic review and meta‐analysis

“…Brazil is a country of continental dimensions with socio‐economic inequalities that are reflected in population health and in research [26]. As a consequence, a national scope is a challenge.…”

Lipids and Sickle Cell Disease

“…2 About 4% of the Brazilian population has a sickle cell trait, and between 60,000 and 100,000 Brazilians have the disease, which translates into an economic burden of more than US$ 400,000,000/year for the Brazilian society. 3 The number of patients affected by this pathology is increasing due to the evolution of treatment and improvement in early diagnosis, as a result of the institution of neonatal screening. 2 Early identification of the disease is important in reducing its morbidity and mortality, especially with the prophylaxis of infections, which are a significant cause of death in children.…”

Biomarcadores cardíacos em pacientes adultos com doenças falciformes

“…Os absenteísmos escolares e trabalhistas agravam as condições sociais por ser uma doença com prevalência maior em grupos economicamente desfavorecidos 16,17 . O custo para o sistema de saúde é significativo e tende a aumentar com o envelhecimento dessa população 18 .…”